Sivasundaram Karnan

9PUBLICATIONS
8CO-AUTHORS
Molecular targetsPlasma physics; fusion plasmas; electrical dischargesMedical infection agents (incl. prions)Medical mycologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 23, 2026
Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells.

|Mar 01, 2026
Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma.

Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan

|Jul 12, 2025
Primary Plasma Cell Leukemia: Recent Advances in Molecular Understanding and Treatment Approaches.

Ichiro Hanamura, Sivasundaram Karnan, Akinobu Ota

|Jan 28, 2024
ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells.

Sivasundaram Karnan, Ichiro Hanamura, Akinobu Ota

|Jul 21, 2023
CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma.

Sivasundaram Karnan, Akinobu Ota, Hideki Murakami

|Jun 21, 2023
Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma.

Maho Onda, Akinobu Ota, Kunihiro Ito

Pageof 2

Frequent Collaborators

9 joint publications

Akinobu Ota

5 joint publications

Md Wahiduzzaman

5 joint publications

Hiroyuki Konishi

5 joint publications

Ichiro Hanamura